FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
View all comments(0)
Sept 24 (Reuters) - FibroGen Inc FGEN.O:
FIBROGEN INITIATES PHASE 2 MONOTHERAPY TRIAL OF FG-3246, A FIRST-IN-CLASS CD46 TARGETING ADC, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
FIBROGEN INC - INTERIM ANALYSIS OF TRIAL EXPECTED IN 2H 2026
FIBROGEN INC - TOPLINE RESULTS OF FG-3246 IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH MCRPC ENZALUTAMIDE EXPECTED Q4 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Global First Storage ETF Surges 88% Five Weeks After Listing. Is It Too Late to Buy Now?

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.